“The acquisition of Arthrosi allows us to expand our gout pipeline with a highly differentiated new asset. Pozdeutinurad has ...

Swedish Orphan Biovitrum (Sobi) has signed an agreement for the acquisition of US-based biotechnology company Arthrosi ...

Fresh off a $153 million series E round, Arthrosi Therapeutics is skipping an IPO route and is instead being bought up for a ...

Drugmaker Swedish Orphan Biovitrum said on Saturday it had agreed to acquire U.S.-based biotechnology company Arthrosi Therapeutics for up to $1.5 billion to strengthen its portfolio of gout ...

For gout pain that does not respond to conventional therapies, patients’ only remaining option is a drug from Amgen. But this biologic medicine introduces the same problem facing every therapeutic ...

The deal revolves around a drug Sobi claimed could become the “therapy of choice” for people whose gout symptoms persist ...

Swedish Orphan Biovitrum AB ( ($SE:SOBI) ) has shared an announcement. Swedish Orphan Biovitrum AB (Sobi) has announced its acquisition of ...

Most TikTok videos inaccurately portray gout flares as a personal choice that can be alleviated through a healthy diet, ...

Gout flare in the hand of an elderly person Researchers evaluated the efficacy and safety of anakinra for the treatment of acute gout flares. Undergoing 5 days of therapy with the IL-1 receptor ...

Gout is a painful form of arthritis that affects the joints. Flare-ups often target the joint of the big toe. Gout is caused by a buildup of too much uric acid in your body. The excess uric acid ...

Expands Sobi’s pipeline with a highly differentiated new Phase 3 asset in GoutAcquisition expected to be highly accretive to Sobi’s mid- to long-term growth and margin trajectory Sobi® (STO:SOBI) has ...